Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 – 9 (cancelled)

Claim 10 (previously presented) A method of reducing the inhibition of endogenous 13-HODE synthesis which may occur when omega-3 fatty acids are orally administered to a subject which comprises orally administering to the subject an effective amount of an omega-3 fatty acids formulation comprising 13-HODE.

Claim 11 (currently amended) ~~The method of claim 1~~A method of reducing or inhibiting cell hyperlasia and restoring vessel wall biocompatibility in a mammal or human in need of such treatment, comprising administering orally an amount of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) effective to reduce or inhibit vessel wall thrombogenicity, wherein 13-HODE is administered as a pharmaceutical composition comprising 13-HODE and omega-3 fatty acids.

Claim 12 (previously presented) The method of claim 10, wherein the omega-3 fatty acid formulation comprises EPA, DHA, a derivative of EPA, a derivative of DHA, or a combination thereof.

Claim 13 (previously presented) The method of claim 10, wherein the omega-3 fatty acid formulation comprises ethyl-EPA, ethyl-DHA, or both.

Claim 14 (previously presented) An oral pharmaceutical composition comprising 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) in its free form and at least one omega-3 fatty acid selected from the group consisting of EPA, DHA, a derivative of EPA and a derivative of DHA.

Claim 15 (previously presented) The oral pharmaceutical composition of claim 14 and further comprising a pharmaceutically acceptable carrier.

Claim 16 (previously presented) The oral pharmaceutical composition of claim 14 wherein the daily dose of 13-HODE is equal to or less than 100 mg.

Claim 17 (previously presented) The oral pharmaceutical composition of claim 15, wherein the carrier is a mono-, di- or triglyceride oil.

Claim 18 (previously presented) The oral pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of corn, sunflower, safflower, cottonseed, grape seed, olive, evening primrose, borage, fish body, and fish liver oils.

Claim 19 (previously presented) The oral pharmaceutical composition of claim 15, wherein the carrier is an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.

Claim 20 (previously presented) The oral pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of ethyl-eicosapentaenoic (ethyl-EPA), oleic, linoleic, alpha-linolenic, stearidonic, gamma-linolenic, dihomogammalinolenic, arachidonic, docosapentaenoic and docosahexaenoic (ethyl-DHA).

Claim 21 (previously presented) The oral pharmaceutical composition of claim 14, wherein the composition is administered in the form selected from the group consisting of tablets, dragees, capsules, granules, solutions, suspensions and lyophilized compositions.

Claim 22 (previously presented) The oral pharmaceutical composition of claim 14 wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.

Claim 23 (previously presented) The oral pharmaceutical composition of claim 14 wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.

Claims 24 – 25 (cancelled)

Claim 26 (previously presented) The oral pharmaceutical composition of claim 14, wherein the omega-3 fatty acid is selected from the group consisting of ethyl-EPA and ethyl-DHA.

Claims 27 – 32 (cancelled)